UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: November 3, 1997
(Date of earliest event reported)
LIDAK PHARMACEUTICALS
(Exact name of registrant as specified in its charter)
CALIFORNIA
(State or other jurisdiction of incorporation)
0-18734 33-0314804
(Commission File Number) (IRS Employer Identification No.)
11077 North Torrey Pines Road, La Jolla, California 92037
(Address of principal executive offices) (Zip code)
(619) 558-0364
(Registrants telephone number, including area code)
<PAGE>
Item 5. OTHER EVENTS
On November 4, 1997, the Company annouced the appointment of Mr. Jeffery B.
Weinress to the position of Vice President and Chief Financial Officer
effective November 3, 1997. Mr. Weinress replaces Susan Yeagley Sullivan
who resigned from the position in October, 1997.
Item 7. Financial Statements and Exhibits
(c) Exhibits
(i) Exhibit 99 -- Press Release dated November 4, 1997.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
LIDAK PHARMACEUTICALS
Date: November 12, 1997 By:\s\David H. Katz
-------------------
David H. Katz, M.D.
President and Chief Executive Officer
<PAGE>
EXHIBIT 99
DATE: NOVEMBER 4, 1997 LIDAK PHARMACEUTICALS CONTACT: Lisa Dawn Katz
NEWS RELEASE Director, Corporate
RELEASE DATE: IMMEDIATE Communications &
Investor Relations
LIDAK Pharmaceuticals
(619) 558-0364, ext. 256
LIDAK PHARMACEUTICALS APPOINTS JEFFERY WEINRESS
AS NEW CHIEF FINANCIAL OFFICER
LA JOLLA, CALIFORNIA -- November 4, 1997 -- LIDAK Pharmaceuticals (Nasdaq NM:
LDAKA) announced that Jeffery B. Weinress joined the Company on November 3,
1997 as vice president and chief financial officer.
Mr. Weinress has blended a distinguished academic background into a
professional career in the banking and investment banking industries and in
corporate officer roles during the past 23 years. A cum laude graduate of
Dartmouth College with distinction in economics, Mr. Weinress studied at
Princeton and at Harvard University where he completed a Masters degree in
Asian Studies and earned his MBA in finance from Harvard Graduate School of
Business Administration.
Mr. Weinress began his professional career at Bank of America, where he
served as a vice president and head of the Financial Services Group, Asia
Division, and as a vice president in the Bank's Energy and Project Finance
Groups. At Hambrecht and Quist he was co-manager of the Energy Finance
Group and at First Interstate Bank he was managing director. Mr. Weinress then
became vice president - project finance for Energy Factors, Inc., managing
private and public financings totaling over $400 million. He joined Energy
America Incorporated as executive vice president and chief financial officer
and was responsible for financings totaling over $200 million. Mr. Weinress
served as executive vice president and chief financial officer at Omega
Environmental, Inc. until mid-1997.
Commenting on the appointment, David H. Katz, M.D., LIDAK's president and
chief executive officer, stated, "We feel that Jeff will be an outstanding
addition to LIDAK's team. His broad experience in accounting, finance and
SEC reporting, banking and investor relations is a perfect complement to our
present staff. Jeff's extensive experience in the upper management of
publicly held companies, his broad based knowledge of investment banking,
public offerings, private placements and SEC procedures, as well as his
expertise in financial reporting, acquisitions, cash management, contract
negotiations, and bank relations will be extremely valuable to LIDAK."
LIDAK Pharmaceuticals is developing therapeutic products against virally
caused diseases, inflammatory disorders, allergies and asthma, and cancer.
# # #
The information contained in this press release, including any forward looking
statements contained herein, should be reviewed in conjunction with the
Company's Annual Report on Form 10-K and other publicly available information
regarding the Company, copies of which are available from the Company upon
request. Such publicly available information sets forth many risks and
uncertainties related to the Company's business and such statements, including
risks and uncertainties related to drug development and clinical trials. Final
review decisions made by the FDA and other regulatory agencies concerning
clinical trial results are unpredictable and outside of the influence and/or
control of the company.
